Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
about
Ganoderma lucidum(Reishi mushroom) for cancer treatmentPlatinum versus non-platinum chemotherapy regimens for small cell lung cancerGanoderma lucidum(Reishi mushroom) for cancer treatmentPrediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantationAdoptive immunotherapy with interleukin-2 & induced killer cells in non-small cell lung cancer: A systematic review & meta-analysisLaunching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculatureBrain imaging in drug R&D.Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaKanglaite injection plus chemotherapy versus chemotherapy alone for non-small cell lung cancer patients: A systematic review and meta-analysis.Attenuated effects of Jianpi Qushi herbs on patients receiving FOLFOX4 after colorectal cancer surgery: A meta-analysis.Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review studyResponse Evaluation of Chemotherapy for Lung Cancer.Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancerPreclinical multimodality phantom design for quality assurance of tumor size measurementTopo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma.The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic reviewThe effects of applying breast compression in dynamic contrast material-enhanced MR imagingPlatinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis.The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment.Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlationImaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review.Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy.Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas.Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods.Drug development in oncology: classical cytotoxics and molecularly targeted agents.Diffusion-Weighted MRI in the Assessment of Early Treatment Response in Patients with Squamous-Cell Carcinoma of the Head and Neck: Comparison with Morphological and PET/CT Findings.Factors associated with false-negative endoscopic biopsy results after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinomaMolecular Magnetic Resonance Imaging of Tumor Response to Therapy.The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancerA Low-Cost Fiducial Reference Phantom for Computed TomographyEvaluation of a cloud-based local-read paradigm for imaging evaluations in oncology clinical trials for lung cancerA pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumoursThe Value of PET Imaging in Patients with Localized Gastroesophageal Cancer.Correlation between histological grade and positron emission tomography parameters in cervical carcinoma.Efficacy of minimally invasive therapies on unresectable pancreatic cancer.Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.
P2860
Q24185921-89B4E174-F383-4007-A5E8-49D991140082Q24188039-BCB093C3-231B-413C-8F9F-A76A91E281EFQ24202814-4F3E1B00-9008-4CC1-BC13-0865503B920AQ26772329-E5327DC9-A23D-4BDA-89D3-0B083B566092Q28072200-965D7AD5-F1ED-4A7D-BEB5-D57C34E6BAEFQ28475128-D32369AF-4FC0-4F82-AB63-755B8239FE85Q31019812-2760EE04-9F42-4BE9-9477-C377B16870F8Q33382596-F52A67B2-E252-40EB-974A-AD81871692EAQ33414373-D3A9F64B-3036-40D5-B0A7-B241390A140FQ33429295-D25EE5AC-F094-40B4-8BEB-A52649C0040CQ33506194-90E1E467-D1C4-4D09-8B6A-7B03C64368C6Q33567345-C0A60621-0F42-4665-9744-57FAEC1BF192Q33577811-E6D20476-B8E7-4AA6-B866-25146F360FB0Q34035194-EC9014CA-97F7-454F-B9D9-C74F85C4F750Q34433737-A71FF7C8-6E24-4B2C-8A97-F44BB511EA16Q34550662-65D01874-1DAC-4147-AEEA-9D4D1AC39C99Q34566213-A4E9770E-1C7B-4A97-8377-DDD79604EE2BQ34681250-0FC8744D-00FC-4324-BA6F-F86DEF5166D2Q34852173-62685707-90BB-4AAE-B234-21DACEA6011AQ34865296-761552C9-4B33-4549-8C94-74AE68F66C66Q34982068-47E8DBA6-F18C-4BCA-AF8D-0A4FD990D2C4Q35051942-A0262062-CC05-4EB2-9877-5DF6758B78E6Q35142268-B56D8342-83A1-4FEA-9C9B-3ABA2A87DC6CQ35201353-F918886D-6B0E-4693-BDAB-C92EF5402F92Q35739540-0B6AF32D-4163-4DBD-9837-61D9E16BF2E7Q35800552-DE4F4037-A253-4A86-918D-734A361E8AF3Q35800569-35AE0B58-19A3-4AD3-AB0E-22BE31E64408Q35827606-23F325BC-55D2-4EBF-B519-754FA3357627Q35840022-B1D871FB-C054-497A-B6A8-48DE4D4CEF2AQ36009402-AF7EEB7E-8D3C-4BAA-BA27-02ABE07A986FQ36123378-4DFE43F3-C735-48FB-AA73-80AFBCC75290Q36134671-5E1ECB05-F611-45DE-BF87-28F31B66334AQ36299395-DD566E55-B40E-47F6-9CE3-F61EB84BEBE3Q36345062-EAC20692-BF4E-4CA4-8B46-625797D8F7E7Q36696431-6143AFF7-076E-4D60-81DC-3702D1533D6FQ37076617-229DB090-850A-467E-9E85-7BEBDA37365AQ37106866-865C46CD-57CB-4DF2-9BE6-240434D5BD75Q37354138-C6F5CFF1-1C9A-4726-B886-B4470E8C9E43Q37449210-BAD8CFDD-4EAD-44EA-AAF7-4F205C983BA4Q37450606-617B4404-06B5-44B9-B035-6FB6537E1255
P2860
Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
@en
Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
@nl
type
label
Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
@en
Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
@nl
prefLabel
Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
@en
Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
@nl
P2093
P356
P1476
Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
@en
P2093
Chul Won Jung
Joon Oh Park
Keunchil Park
Kihyun Kim
Kyung Soo Lee
Mark Hong Lee
Seo Young Song
Soon Il Lee
Won Ki Kang
Won Seog Kim
P304
P356
10.1093/JJCO/HYG093
P577
2003-10-01T00:00:00Z